Home Cart Sign in  
Chemical Structure| 104206-65-7 Chemical Structure| 104206-65-7

Structure of Nitisinone
CAS No.: 104206-65-7

Chemical Structure| 104206-65-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nitisinone is an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase.

Synonyms: NTBC; Nitisone; SC0735

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations      Show More

Hayashi, Kazuki ; Horisaka, Kisara ; Harada, Yoshiyuki ; Ogawa, Yuta ; Yamashita, Takako ; Kitano, Taku , et al.

Abstract: Polyploidy is frequently enhanced under pathological conditions, such as tissue injury and cancer in humans. Polyploidization is critically involved in cancer evolution, including cancer initiation and the acquisition of drug resistance. However, the effect of polyploidy on cell fate remains unclear. In this study, we explored the effects of polyploidization on cellular responses to and progression. Through various comparisons based on ploidy stratifications of cultured cells, we found that polyploidization and the accumulation of genomic mutually induce each other, resulting in polyploid cells consistently containing more genomic than diploid cells under both physiological and stress conditions. Notably, despite substantial , polyploid cells demonstrated a higher tolerance to its impact, exhibiting delayed arrest and reduced secretion of inflammatory cytokines associated with DNA damage-induced senescence. Consistently, in mice with ploidy tracing, hepatocytes with high ploidy appeared to potentially persist in the damaged liver, while being susceptible to . Polyploidy acts as a reservoir of genomic damage by mitigating the impact of , while simultaneously enhancing its accumulation.

Purchased from AmBeed:

Parkins, Andrew ; Pantouris, Georgios ;

Abstract: 4-hydroxyphenylpyruvate dioxygenase (HPPD) is a key enzyme involved in the pathogenesis of tyrosinemia III and cancer. Herein, we describe a spectroscopy-based assay to detect HPPD dioxygenase activity in the presence or absence of small-mol. modulators. We describe steps for transformation, expression, and purification of HPPD and preparation of the assay plate. We detail initiation and completion of the enzymic reaction followed by detection of remaining substrate in the form of enol-HPP/borate complex. This assay is applicable for high-throughput screening. For complete details on the use and execution of this protocol, please refer to Parkins et al.1

Purchased from AmBeed:

Tiyaboonchai, Amita ; Vonada, Anne ; Posey, Jeffrey ; Pelz, Carl ; Wakefield, Leslie ; Grompe, Markus

Abstract: Expression of guide RNAs in the CRISPR/Cas9 system typically requires the use of RNA polymerase III promoters, which are not cell-type specific. Flanking the gRNA with self-cleaving ribozyme motifs to create a self-cleaving gRNA overcomes this limitation. Here, we use self-cleaving gRNAs to create drug-selectable gene editing events in specific hepatocyte loci. A recombinant Adeno Associated Virus vector targeting the Albumin locus with a promoterless self-cleaving gRNA to create drug resistance is linked in cis with the therapeutic transgene. Gene expression of both are dependent on homologous recombination into the target locus. In vivo drug selection for the precisely edited hepatocytes allows >30-fold expansion of gene-edited cells and results in therapeutic levels of a human Factor 9 transgene. Importantly, self-cleaving gRNA expression is also achieved after targeting weak hepatocyte genes. We conclude that self-cleaving gRNAs are a powerful system to enable cell-type specific in vivo drug resistance for therapeutic gene editing applications.

Purchased from AmBeed:

Alternative Products

Product Details of Nitisinone

CAS No. :104206-65-7
Formula : C14H10F3NO5
M.W : 329.23
SMILES Code : O=C1C(C(C2=CC=C(C(F)(F)F)C=C2[N+]([O-])=O)=O)C(CCC1)=O
Synonyms :
NTBC; Nitisone; SC0735
MDL No. :MFCD01752192
InChI Key :OUBCNLGXQFSTLU-UHFFFAOYSA-N
Pubchem ID :115355

Safety of Nitisinone

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302+H312+H332-H315-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Nitisinone is an orally active, competitive, and reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) with an IC50 of 173 nM. It increases tyrosine levels in a dose-dependent manner and is utilized in research related to hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder, and albinism[1].[2].[3].[4].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01916382 Alkaptonuria PHASE3 UNKNOWN 2020-02-02 Royal Liverpool Hospital, Live... More >>rpool, Merseyside, L7 8XP, United Kingdom Less <<
NCT01828463 Alkaptonuria PHASE2 COMPLETED 2025-12-13 Royal Liverpool Hospital, Live... More >>rpool, Merseyside, L7 8XP, United Kingdom Less <<
NCT01838655 Albinism|Vision Loss PHASE1|PHASE2 COMPLETED 2017-02-07 National Institutes of Health ... More >>Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, 20892, United States Less <<
NCT06227429 Hereditary Tyrosinemia, Type I RECRUITING 2027-06-30 Swedish Orphan Biovitrum Resea... More >>rch Site, Beijing, China|Swedish Orphan Biovitrum Research Site, Chongqing, China|Swedish Orphan Biovitrum Research Site, Hefei, China|Swedish Orphan Biovitrum Research Site, Wuhan, China Less <<
NCT01734889 Hereditary Tyrosinemia, Type I PHASE1 COMPLETED 2025-03-13 Hopital Necker, Paris, France|... More >>Universit?tsklinikum Düsseldorf, Düsseldorf, Germany|Universit?tsklinikum Heidelberg, Heidelberg, Germany|Klinikum der Universit?t München, München, Germany|Birmingham Children's Hospital, Birmingham, United Kingdom|Evelina Children's Hospital, St Thomas' Hospital, London, United Kingdom|St Mary's Hospital, Manchester, United Kingdom Less <<
NCT02750332 Hereditary Tyrosinemia, Type I PHASE1 COMPLETED 2025-01-16 Bloemfontein Early Phase Clini... More >>cal Unit, PAREXEL International (South Africa), Bloemfontein, Free State, 9301, South Africa Less <<
NCT02320084 Hereditary Tyrosinemia, Type I COMPLETED 2019-09-30 Swedish Orphan Biovitrum Inves... More >>tigational Site, Innsbruck, Austria|Swedish Orphan Biovitrum Investigational Site, Wien, Austria|Swedish Orphan Biovitrum Investigational Site, Antwerpen, Belgium|Swedish Orphan Biovitrum Investigational Site, Brussels, Belgium|Swedish Orphan Biovitrum Investigational Site, Leuven, Belgium|Swedish Orphan Biovitrum Investigational Site, Montegnée, Belgium|Swedish Orphan Biovitrum Investigational Site, Woluwe-Saint-Lambert, Belgium|Swedish Orphan Biovitrum Investigational Site, Prague, Czechia|Swedish Orphan Biovitrum Investigational Site, Copenhagen, Denmark|Swedish Orphan Biovitrum Investigational Site, Tampere, Finland|Swedish Orphan Biovitrum Investigational Site, Turku, Finland|Swedish Orphan Biovitrum Investigational Site, Angers, France|Swedish Oprhan Biovitrum Investigational Site, Lille, France|Swedish Orphan Biovitrum Investigational Site, Lyon, France|Swedish Orphan Biovitrum Investigational Site, Nantes, France|Swedish Oprhan Biovitrum Investigational Site, Paris, France|Swedish Orphan Biovitrum Investigational Site, Paris, France|Swedish Orphan Biovitrum Investigational Site, Talence, France|Swedish Orphan Biovitrum Investigational Site, Düsseldorf, Germany|Swedish Orphan Biovitrum Investigational Site, Erlangen, Germany|Swedish Orphan Biovitrum Investigational Site, Freiburg, Germany|Swedish Orphan Biovitrum Investigational Site, Hannover, Germany|Swedish Orphan Biovitrum Investigational Site, Heidelberg, Germany|Swedish Orphan Biovitrum Investigational Site, Leipzig, Germany|Swedish Orphan Biovitrum Investigational Site, Magdeburg, Germany|Swedish Orphan Biovitrum Investigational Site, München, Germany|Swedish Orphan Biovitrum Investigational Site, Reutlingen, Germany|Swedish Orphan Biovitrum Investigational Site, Budapest, Hungary|Swedish Oprhan Biovitrum Investigational Site, Szeged, Hungary|Swedish Orphan Biovitrum Investigational Site, Dublin, Ireland|Swedish Orphan Biovitrum Investigational Site, Bari, Italy|Swedish Orphan Biovitrum Investigational Site, Catania, Italy|Swedish Orphan Biovitrum Investigational Site, Firenze, Italy|Swedish Orphan Biovitrum Investigational Site, Milano, Italy|Swedish Orphan Biovitrum Investigational Site, Monza, Italy|Swedish Orphan Biovitrum Investigational Site, Napoli, Italy|Swedish Orphan Biovitrum Investigational Site, Padova, Italy|Swedish Orphan Biovitrum Investigational Site, Roma, Italy|Swedish Orphan Biovitrum Investigational Site, Saliceto, Italy|Swedish Orphan Biovitrum Investigational Site, Torino, Italy|Swedish Oprhan Biovitrum Investigational Site, Amsterdam, Netherlands|Swedish Orphan Biovitrum Investigational Site, Utrecht, Netherlands|Swedish Orphan Biovitrum Investigational Site, Fredrikstad, Norway|Swedish Orphan Biovitrum Investigational Site, Levanger, Norway|Swedish Oprhan Biovitrum Investigational Site, Oslo, Norway|Swedish Orphan Biovitrum Investigational Site, Oslo, Norway|Swedish Orphan Biovitrum Investigational Site, Troms?, Norway|Swedish Oprhan Biovitrum Investigational Site, Warsaw, Poland|Swedish Orphan Biovitrum Investigational Site, Warszawa, Poland|Swedish Orphan Biovitrum Investigational Site, Coimbra, Portugal|Swedish Orphan Biovitrum Investigational Site, Albacete, Spain|Swedish Orphan Biovitrum Investigational Site, Almeria, Spain|Swedish Orphan Biovitrum Investigational Site, Badalona, Spain|Swedish Orphan Biovitrum Investigational Site, Barakaldo, Spain|Swedish Orphan Biovitrum Investigational Site, Barcelona, Spain|Swedish Orphan Biovitrum Investigational Site, Las Palmas de Gran Canaria, Spain|Swedish Oprhan Biovitrum Investigational Site, Madrid, Spain|Swedish Orphan Biovitrum Investigational Site, Madrid, Spain|Swedish Orphan Biovitrum Investigational Site, Malaga, Spain|Swedish Orphan Biovitrum Investigational Site, Murcia, Spain|Swedish Orphan Biovitrum Investigational Site, Mérida, Spain|Swedish Orphan Biovitrum Investigational Site, Pamplona, Spain|Swedish Orphan Biovitrum Investigational Site, Santiago, Spain|Swedish Orphan Biovitrum Investigational Site, Sevilla, Spain|Swedish Orphan Biovitrum Investigational Site, Valencia, Spain|Swedish Orphan Biovitrum Investigational Site, G?teborg, Sweden|Swedish Orphan Biovitrum Investigational Site, Stockholm, 14186, Sweden|Swedish Orphan Biovitrum Investigational Site, Stockholm, Sweden|Swedish Orphan Biovitrum Investigational Site, Ume?, Sweden|Swedish Orphan Biovitrum Investigational Site, Uppsala, Sweden|Swedish Oprhan Biovitrum Investigational Site, Birmingham, United Kingdom|Swedish Orphan Biovitrum Investigational Site, Bradford, United Kingdom|Swedish Oprhan Biovitrum Investigational Site, London, United Kingdom|Swedish Orphan Biovitrum Investigational Site, London, United Kingdom|Swedish Oprhan Biovitrum Investigational Site, Manchester, United Kingdom|Swedish Orphan Biovitrum Investigational Site, Manchester, United Kingdom|Swedish Orphan Biovitrum Investigational Site, Sheffield, United Kingdom Less <<
NCT01390077 Alkaptonuria PHASE2|PHASE3 COMPLETED 2025-07-16 University of California San D... More >>iego, La Jolla, California, 92093, United States Less <<
NCT02323529 Hereditary Tyrosinemia, Type I PHASE3 COMPLETED 2025-09-15 Swedish Orphan Biovitrum Inves... More >>tigational Site, Brussels, Belgium|Swedish Orphan Biovitrum Investigational Site, Copenhagen, Denmark|Swedish Orphan Biovitrum Investigational Site, Lyon, France|Swedish Orphan Biovitrum Investigational Site, Giessen, Germany|Swedish Orphan Biovitrum Investigational Site, Reutlingen, Germany|Swedish Orphan Biovitrum Investigational site, Gothenburg, Sweden Less <<
NCT00004333 Tyrosinemia, Type I PHASE2 COMPLETED - -
NCT00004443 Tyrosinemia I COMPLETED 2025-09-06 Oregon Health Sciences Univers... More >>ity, Portland, Oregon, 97201-3098, United States|University of Washington School of Medicine, Seattle, Washington, 98195, United States|Hopital Sainte Justine, Montreal, Quebec, H3T 1C5, Canada Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.04mL

0.61mL

0.30mL

15.19mL

3.04mL

1.52mL

30.37mL

6.07mL

3.04mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories